On August 19, Moderna and Merck reported successful Phase 3 trial results for a personalized vaccine targeting melanoma. Following these positive clinical outcomes, stocks within the vaccine sector experienced a significant rally. The trial success marks a key milestone in the development of cancer treatment technologies and its immediate impact on market performance.
